Horizon Europe Avrupa Birliği
Neutral-Atom Platform Technologies
This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: • Fully programmable industry-ready quan…
Horizon Europe · Avrupa Birliği
Development of innovative antimicrobials against pathogens resistant to antimicrobials
Açık
AB Ufuk Avrupa programı tarafından 5 hibe bekleniyor; proje başına €8 milyon – €10 milyon; toplam bütçe €44,2 milyon. Başvurular 17 Şubat 2027 tarihinde kapanıyor (AB çağrıları genellikle Brüksel saatiyle 17:00’de kapanır). AB üye ülkelerindeki ve Türkiye gibi ortak ülkelerdeki kuruluşlar genellikle katılabilir; konu koşulları belirleyicidir.
- Son başvuru
- 17 Şubat 2027 (94 gün kaldı)
- Hibe tutarı
- Proje başına €8 milyon – €10 milyon
- Toplam bütçe
- €44,2 milyon
- Destek oranı
- Uygun maliyetlerin %100’ü Bu program için standart kural; çağrı farklı olabilir.
- Toplam bütçe
- €44,2 milyon
- Beklenen hibe sayısı
- 5
- Faaliyet türü
- HORIZON Research and Innovation Actions · HORIZON Action Grant Budget-Based
- Olası başvuru sahipleri
- Şirketler, KOBİ’ler / girişimler, Kâr amacı gütmeyenler, Üniversiteler ve araştırma, Kamu kurumları Kaynak kategorilerinden veya program kurallarından; uygunluğa çağrı karar verir.
- Fon sağlayıcı
- Horizon Europe (HORIZON)
- Referans
- HORIZON-HLTH-2027-01-DISEASE-08
- Çağrı
- HORIZON-HLTH-2027-01
- Son kontrol
- 14 Kasım 2026
Resmi açıklamalar fon sağlayıcının dilindedir (çoğunlukla İngilizce); bu sayfadaki özet ve temel bilgiler Türkçedir.
Beklenen sonuçlar
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
• The scientific and clinical communities have a better understanding of and access to new and innovative products for the treatment of antimicrobial resistant bacteria and fungi, as well as for further clinical investigation.
• Candidate therapies are available to treat patients for antimicrobial resistant bacteria and fungi, increasing therapeutic options for clinical deployment in the fight against Antimicrobial Resistance (AMR).
Kapsam
The rapid rise of AMR presents a formidable threat to public health, challenging our ability to treat infections that were once easily managed with standard antimicrobials. As pathogens continually adapt and develop resistance to existing drugs, the efficacy of these treatments diminishes, leading to more severe and prolonged illnesses, increased healthcare costs and productivity losses, and higher mortality rates. This escalating crisis underscores an urgent need for viable therapeutic alternatives required to reduce the burden of diseases caused by antibiotic resistance. Innovative solutions are crucial to maintaining effective disease management and safeguarding public health.
Proposals should pursue the development of innovative and effective antibacterial and antifungal agents, including antibody-based therapies, which meet at least one of the four World Health Organization (WHO) innovation criteria [1] , namely: i) new chemical class, ii) new target, iii) new mode of action and iv) no evidence of cross-resistance.
Tam metni oku
This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the implementation of the European Medical Countermeasures Strategy [2] and the forthcoming Critical Medicines Act [3] .
Proposals under this topic should not pursue the development of phage-therapies.
Applicants should explicitly state in their proposal which of the following pathogens is targeted and the proposed work should address only this specific pathogen. The proposed work should pursue the development of existing therapeutic candidates targeting exclusively one of the following pathogens:
• Carbapenem resistant Acinetobacter baumanii (CRAB)
• Carbapenem-resistant Enterobacterales (CRE) and third-generation cephalosporin-resistant Enterobacterales (C3GRE)
• Carbapenem resistant Pseudomonas aeruginosa
• Methicillin-Resistant Staphylococcus aureus (MRSA)
• (Drug)-resistant Aspergillus fumigatus
• (Drug)-resistant Candida spp
Identifying a specific pathogen does not preclude the exploration of these candidates' effects on other bacteria or fungi. Proposals should thus aim to accelerate testing of novel candidates in human trials, diversify and accelerate the global prophylactic and therapeutic research and development portfolio for AMR bacterial and fungal infections, and to strengthen the leading role of the EU in prophylactic and therapeutic research and development.
Proposals should address all the following areas:
• If necessary, finalisation of in-vivo tests in at least one animal model or, if available in humanised immune system animal models, to demonstrate the protective function of the therapeutics deemed sufficient for moving to first clinical trials.
• If requested by regulators as pre-requisite for clinical studies, in-vivo tests in a non-human primate model.
• Production of batches of the most promising antimicrobials candidates according to the Good Manufacturing Practices (GMP) [4] .
• In human clinical…
Kimler başvurabilir
Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).
Başvuru sahibi kategorileri yalnızca bir başlangıç noktasıdır. Uygunluğa resmi çağrı karar verir.
Konular
Antibiotics Antimicrobial resistance Antimicrobials Clinical development, Phase I Clinical trials Disease control Drug development, clinical phases Fungi Infectious diseases MRSA Patient safety Acinetobacter Bamanii Candida Carbapenem Enterobacterales anti-microbials antimicrobials aspergillus cephalosporin
Zamanlama
Single-stage call. Next deadline 2027-02-17. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).
Nasıl başvurulur
- Portaldaki konunun tamamını okuyun: beklenen sonuçlar, kapsam, faaliyet türü ve ülke veya konsorsiyum kısıtlamaları dahil uygunluk koşulları.
- Kuruluşunuzu AB Funding & Tenders Portalına kaydederek her ortak için bir PIC numarası alın.
- İşbirliğine dayalı araştırma ve yenilik projeleri genellikle üç farklı AB üye ülkesi veya ortak ülkeden en az üç bağımsız ortak gerektirir (Türkiye Ufuk Avrupa’ya ortak ülkedir). Bu konudaki kuralı doğrulayın.
- Bölüm A’yı (portalda doldurulan idari formlar ve bütçe) ve Bölüm B’yi (bu faaliyet türü için resmi şablondaki teknik açıklama) hazırlayın.
- Son başvuru günü kapanış saatinden önce portal üzerinden gönderin. Geç başvurular kabul edilmez.
From the call text
- Who can apply
- Not stated in the call text we hold — check the official page
- Company stage
- Not stated in the call text we hold — check the official page
- Single applicant or consortium
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where applicants must be based
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where to apply
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Resmi kaynaklar
Bu sayfadaki bilgiler resmi kaynaktan alınmıştır ve en son 14 Kasım 2026 tarihinde kontrol edilmiştir. Sonraki değişiklikler dahil, fon sağlayıcının kendi belgeleri her zaman önceliklidir.
Horizon Europe: diğer çağrılar
Horizon Europe Avrupa Birliği
Next-Generation QKD Systems
This action will strengthen Europe's strategic autonomy in quantum-secure communications by advancing core QKD technologies and integration capabilities. Expected results…
Horizon Europe Avrupa Birliği
Quantum Experimental Pilot Lines for Quantum Technologies
This action will strengthen Europe's leadership and strategic autonomy in quantum technologies by advancing experimental pilot line capacities as a vital stepping stone t…
Horizon Europe Avrupa Birliği
Quantum-Testing Infrastructure for Quantum Technologies
This action will establish a pan-European open-access testing and experimentation infrastructure for quantum technologies, enabling systematic validation and certificatio…
Horizon Europe Avrupa Birliği
Superconducting Platform Technologies
This action will consolidate Europe’s position in superconducting quantum computing through: • Establishment of a full-stack superconducting quantum computer aiming at 1.…